摘要
目的了解2004-2006年长江流域6城市脑血管循环药物应用状况。方法对6城市入网医院2004-2006年临床应用的脑血管循环药物的数据资料进行统计分析,从用药金额和用药频度(DDDs)进行排序。结果长江流域6城市脑血管循环药物的用药总金额2005年和2006年分别较上一年增长了19.13%、16.55%,总用药频度2005年较上一年增长了42.16%,而2006年比2005年下降了18.76%。在6城市3 a总用药频度排序中始终位于前3位的药物是脑蛋白水解物、阿米三嗪-萝巴新、氟桂利嗪,3 a总用药金额排序中始终位于前3位的是阿米三嗪-萝巴新、小牛血去蛋白提取物、脑蛋白水解物。结论长江流域6城市脑血管循环药物3 a内占主导的药物变化不大,且各城市占主导的脑血管循环药物也相似,但也有一些药物其金额排序与DDDs排序相差很大的,所以在面对种类繁多的脑血管循环药物时,临床医生需要考虑如何合理使用的问题。
AIM To analyze the utilization of drugs on cerebrovascular circulation in hospitals of 6 main cities in Yangtze River valley during 2004-2006. METHODS The drugs on cerebrovascular circulation were analyzed according to the orders of sum and defined daily dose （DDDs） in each city, RESULTS The total annual cost of the drugs of 2005 increased by 19.13 % compared to that of 2004; and the total cost of 2006 increased by 16.55 % compared to that of 2005. The total DDDs of 2005 increased by 42.16 % compared to last year and the total DDDs of 2006 decreased by 18.76 % compared to 2005. In the ranking column of total DDDs, the drugs which ranked the highest places were cerebrolysin, almitrine-raubasine, flunarizine. The ranking column of total cost indicated that almitrine-raubasine, deproteinized hemoderivative of calf blood, cerebrolysin ranked the former three places. CONCLUSION The main drugs on cerebrovascular circulation changed little during 3 years and the main drugs used in each city are similar. However, there are still some drugs of which sum ranks are different from their DDDs. Facing to various drugs for cerebrovascular circulation, doctors should take consideration before they prescribe this kind of drugs to the patients.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2008年第2期112-115,共4页
Chinese Journal of New Drugs and Clinical Remedies
关键词
脑血管循环
药物利用
经济学
药学
长江流域
valleycerebrovascular circulation
drug utilization
economics, pharmaceutical
Yangtze River
作者简介
徐华娥（1979-），女，江苏盐城人，药师，硕士，主要从事临床药学工作。Phn：86—25—8371—4511，ext6979；E—mail：xuhuae@yahoo．com．cn
